4873 English

Yesterday, Nils Brünner, CEO of the Danish Scandion Oncology and Per Norlén, CEO of Swedish Alligator Bioscience came together at the BioStock Studio to discuss their newly forged collaboration. The two companies have recently agreed to explore the anti-tumour effect of Alligator’s mitazalimab in combination with Scandion’s SCO-101 as an addition to chemotherapy in resistant preclinical tumour models. The two CEOs expect that SCO-101 will be able to revert chemotherapy resistance and thereby further strengthen the anti-tumour effects of mitazalimab. 

Watch the full interview with Nils Brünner and Per Norlén below.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev